secwatch.observer — SEC 8-K summary
======================================

Issuer:     OptimizeRx Corp (OPRX)
CIK:        0001448431
Form:       8-K
Filed at:   2026-08-12T20:07:41+00:00
Accession:  0001448431-26-000014
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OptimizeRx Q2 revenue falls 30% to $20.5M, swings to GAAP net loss; reaffirms FY guidance
--------------------------------------------------------------------------------

- Q2 revenue $20.5M, down 30% YoY from $29.2M; GAAP net loss $(0.7)M or $(0.04)/share vs $1.5M net income ($0.08) in Q2 2025.
- Non-GAAP net income $3.1M ($0.16 diluted) vs $3.7M ($0.19) prior year; adjusted EBITDA $4.9M vs $5.8M.
- FY2026 guidance reaffirmed: revenue $95-100M and adjusted EBITDA $21-25M.
- CFO Ed Stelmakh steps down Dec 31, 2026; Andy D'Silva becomes CFO and Heather Favazza CAO effective Jan 1, 2027.
- Stelmakh gets 12 months base salary ($450K/yr), $247.5K bonus lump sum, COBRA; advisory role through Dec 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1448431/000144843126000014/0001448431-26-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1448431/000144843126000014/oprx-20260807.htm
  HTML page:      https://secwatch.observer/filing/0001448431-26-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer